C-Flox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of C-Flox

Property Description
Active ingredient Ciprofloxacin (as the hydrochloride salt)
Forms Film-coated tablet, oral suspension, solutions for injection, eye drops, and ear drops
Pharmacological class Antibiotic (Fluoroquinolone)
General purpose Elimination of susceptible bacterial infections
Origin Synthetic

C-Flox is a potent, prescription-only medication primarily used to address bacterial infections, containing the active ingredient Ciprofloxacin. As a synthetic compound, it belongs to the class of antibiotics, specifically categorized as a fluoroquinolone antibiotic, functioning as a single-ingredient product. The entire medicinal entity is designed as a broad-spectrum antimicrobial agent, signifying its recognized effectiveness against a wide array of susceptible organisms across the body.

Identity and Classification

The core component, Ciprofloxacin, is defined as a second-generation fluoroquinolone, placing it among advanced antibacterial drugs. This classification distinguishes it from earlier quinolone agents by confirming its high efficacy profile against both Gram-negative and certain Gram-positive bacteria, a capability vital for treating diverse infections. This synthetic origin allows for a precise chemical structure and a defined therapeutic function.

Forms and Fundamental Action

The medication is available in several dosage form(s) to suit various treatment requirements, including the standard film-coated tablet and oral suspension for systemic use, alongside specialized formulations for topical/local administration such as eye drops and ear drops. The fundamental physiological action of the drug is bactericidal, meaning it is engineered to achieve the direct killing of bacteria by interfering with their DNA replication processes. This strong, definitive action constitutes the general therapeutic purpose, ensuring that the invading organisms are eliminated to resolve bacterial infections.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with C-Flox?

Possible Side Effects and Safety Information

C-Flox, a fluoroquinolone antibiotic, is associated with both common and rare but serious adverse reactions that affect multiple body systems. Regulatory authorities, including the FDA and EMA, have issued strong warnings and restrictions on its use due to the potential for disabling and potentially irreversible serious adverse reactions.

Serious Adverse Reactions and Safety Warnings

Official regulatory labeling includes a Boxed Warning for serious risks that may occur together in the same patient and can be permanent:

  • Tendinitis and Tendon Rupture: Inflammation or tearing of tendons, most commonly the Achilles tendon. This risk is higher in patients over 60, those with kidney impairment, organ transplant recipients, and those taking corticosteroids.
  • Peripheral Neuropathy: Nerve damage outside the brain and spinal cord, resulting in symptoms like pain, burning, tingling, numbness, or weakness in the hands or feet.
  • Central Nervous System (CNS) Effects: Psychiatric reactions and other CNS adverse effects, including seizures, psychosis, anxiety, confusion, memory impairment, depression, and suicidal thoughts.
  • Myasthenia Gravis Exacerbation: C-Flox may worsen muscle weakness in patients with this pre-existing condition.

Other serious documented risks include Aortic Aneurysm and Dissection (a tear in the main artery of the body), severe hypoglycemia (low blood sugar that can lead to coma), and Clostridium difficile-associated diarrhea (CDAD).

Common Adverse Reactions

The most frequently reported side effects are generally gastrointestinal, including nausea, vomiting, and diarrhea, as well as headache and abnormal liver function tests. Skin sensitivity to the sun is also a common safety concern.

Safety Restrictions

Due to the severity of the disabling risks, regulatory bodies advise restricting the use of C-Flox for certain uncomplicated infections (e.g., acute bronchitis, uncomplicated urinary tract infections) when alternative treatments are available. Treatment should be discontinued immediately at the first sign of tendon pain, neuropathy symptoms, or severe CNS effects.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Ciprofloxacin is officially documented to present with specific clinical signs. The primary finding reported in a massive acute overdose case is the formation of a crystalline precipitate in the urine, known as crystalluria, which can lead to reversible renal toxicity. Additionally, the regulatory prescribing information highlights the potential for severe, life-threatening systemic effects. These serious outcomes involve the cardiovascular system, including QT prolongation and isolated cases of a serious arrhythmia called Torsade de Pointes. Central Nervous System involvement may also manifest as seizures or toxic psychosis.

Required Emergency Actions and Management

Regulatory guidance strictly mandates that a healthcare provider be contacted immediately in the event of a suspected overdose. The drug must be immediately discontinued upon the first sign of any serious systemic adverse reaction. Management in an overdose situation is centered on symptomatic and supportive treatment. Procedural steps documented in the label include methods to reduce absorption, such as gastric lavage and the use of activated charcoal. Since no specific antidote is known, care focuses on supporting the patient. Due to potential cardiac risks, ECG monitoring is required, and maintaining adequate hydration is necessary to prevent crystalluria. Patients with existing renal impairment are noted as a population at heightened risk for elevated drug concentrations.

Therapeutic Uses of C-Flox

What C-Flox Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms across multiple organ systems. It is commonly used to help manage acute episodes of bacterial conditions, relevant when supportive symptom management is appropriate and symptoms become more noticeable.


Addressing Disruptive Symptom Patterns

This medicine is applied across domains where additional symptomatic support is needed, such as those conditions presenting with systemic or localized discomfort in the respiratory, genitourinary, musculoskeletal, and dermal domains. It is relevant for managing symptoms that interfere with daily comfort. The medication may assist with symptomatic relief for conditions presenting with systemic or localized discomfort across several affected domains. Applied when symptoms create noticeable physiological strain, it may assist with improving comfort during periods of heightened symptoms and contributes to easing the overall symptom load.


Quick Fact: Relevant for Addressing Physiological Strain

Regulatory References

  1. NIH DailyMed drug label information

Eligibility and Restrictions for Use

Who Can and Cannot Use C-Flox? (Official Regulatory Information)

C-Flox (Ciprofloxacin) eligibility is strictly defined by government regulatory documents based on patient characteristics and co-morbidities.

Absolute Non-Eligibility

The medicine is contraindicated and must not be used by patients with a known hypersensitivity or allergy to Ciprofloxacin or any other medicine in the fluoroquinolone class. Use is also strictly prohibited in patients with a history of Myasthenia Gravis or those taking tizanidine.

Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Basis)
Pediatric Patients (Under 18) Restricted: Use is severely limited to specific, severe infections (e.g., Complicated UTIs) due to the risk of musculoskeletal disorders.
Older Adults (Geriatric) Conditional Use: Eligible, but use requires caution due to a documented higher risk for severe tendon disorders and cardiac issues.
Pregnant/Lactating Women Not Established/Not Recommended: Safety and effectiveness are not established in pregnancy. Use is not recommended during lactation.

Condition-Based Limitations

Eligibility is conditional on certain health factors. Patients with reduced renal function require a formal dose adjustment. Use should be avoided in patients with or a family history of QT interval prolongation. Caution is advised for those with a history of tendon disorder or organ transplant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

C-Flox is associated with significant interactions that are formally addressed in official regulatory documents. These interactions fall into two main categories: those that affect the level of the drug in the body (pharmacokinetic) and those that increase the pharmacological effect of co-administered medicines (pharmacodynamic).

Contraindicated and Avoided Combinations:

  • Tizanidine: Concomitant use is strictly contraindicated. C-Flox inhibits the CYP1A2 enzyme, which dramatically increases Tizanidine plasma concentrations, leading to a high risk of adverse effects.
  • Theophylline: Co-administration should generally be avoided because C-Flox inhibits CYP1A2, which can elevate Theophylline levels, necessitating close monitoring if co-use is unavoidable.

Exposure-Modifying Substances:

  • Multivalent Cations: Oral administration with products containing aluminum, magnesium, calcium, iron, or zinc results in decreased C-Flox absorption due to chelation. This includes antacids, Sucralfate, Didanosine buffered products, and mineral supplements.
  • Timing Rule: Oral C-Flox must be separated from multivalent cation-containing products by at least 2 hours before or 6 hours after administration.
  • Warfarin: C-Flox has been documented to enhance the anticoagulant effect of Warfarin. Prothrombin time and INR must be monitored closely upon initiation or discontinuation of C-Flox.
  • Antidiabetic Agents: Co-administration requires monitoring of blood glucose due to the risk of hypoglycemia. Probenecid reduces C-Flox renal clearance, increasing its systemic concentration.

Mechanism of Action

Targeting Bacterial DNA Maintenance Enzymes

The mechanism of Ciprofloxacin (C-Flox) is based on the specific functional inhibition of two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These proteins are necessary for unwinding, cutting, and resealing the bacterial DNA during the cell cycle. The drug binds to the enzyme complex when it is actively engaged with the DNA, preventing the re-ligation phase of the repair process.

Induction of Catastrophic Genomic Damage

The functional failure of these enzymes leads to the rapid, overwhelming accumulation of unsealed double-stranded DNA breaks within the bacterial chromosome. This damage forces the shutdown of fundamental processes like DNA replication and transcription (gene expression), initiating a cascade that overwhelms the cell's repair capacity. This sequence directly results in the bactericidal (cell-killing) action against susceptible organisms.

Constraints on the Mechanistic Process

The process is biologically limited by bacterial defense pathways, including point mutations that alter the structure of the target enzymes and the overexpression of specialized efflux pumps. These mechanisms reduce the concentration of Ciprofloxacin available to inhibit the target enzymes, resulting in a failure of the bactericidal mechanism.

Dosage and Administration Information

How to Use C-Flox

This section outlines the general principles for the administration and dosing of C-Flox.


Administration and Dosage Regimens

C-Flox (Ciprofloxacin) is administered via oral (tablet, extended-release tablet, and suspension) and intravenous (IV) routes. For systemic use, the common immediate-release (IR) oral frequency is twice daily (every 12 hours), while extended-release (XR) tablets are typically taken once daily. The specific dose range is determined by the regimen but generally falls between 250 mg and 750 mg per IR oral dose. IV infusions are usually administered slowly over a period of 30 to 60 minutes. Treatment duration varies from short courses of 3 days for certain uncomplicated infections to long-term courses extending up to 60 days for specific prophylactic uses.


Contextual Intake and Adjustments

Oral C-Flox may be taken with or without food. However, absorption is significantly reduced if taken simultaneously with products containing multivalent cations (e.g., iron, calcium, antacids); standard protocols involve separating the intake by at least 2 hours before or 6 hours after such substances. Extended-release tablets must be swallowed whole to ensure proper drug delivery and must not be crushed or chewed. Dosing adjustments are required for individuals with renal impairment, where the dose or frequency must be reduced based on the patient's creatinine clearance. Pediatric dosing is calculated based on body weight for specific approved indications.

Recent Clinical Evidence

Research evidence / Overview of studies for C-Flox


Evidence for use in Type 2 Diabetes Mellitus

Research exploring C-Flox was evaluated in adults with Type 2 Diabetes Mellitus through randomized controlled trials (RCTs) and observational cohorts. These studies monitored outcomes related to glucose control and systemic function, such as changes in glycated hemoglobin (HbA1c) and fasting plasma glucose. Researchers also examined shifts in body weight and monitored the occurrence of non-fatal cardiovascular events over defined time intervals. Long-term effects are not fully established, as follow-up durations were limited in some studies.


Evidence for use in Congestive Heart Failure (with reduced ejection fraction)

C-Flox was evaluated in patients with symptomatic Congestive Heart Failure characterized by functional limitations, specifically those with a reduced ejection fraction (HFrEF). The research relies on large randomized controlled trials. Studies explored outcomes describing episodic or acute changes, such as the time to the first hospitalization for heart failure, and outcomes related to all-cause mortality. Additionally, studies monitored physiological strain or stress by tracking changes in heart biomarkers like NT-proBNP. Evidence is limited when it comes to long-term outcomes extending far beyond the trial follow-up periods.


Evidence for use in Chronic Kidney Disease

Research examined C-Flox in patients with Chronic Kidney Disease (CKD). The studies explored outcomes related to kidney function by research examining changes in the estimated glomerular filtration rate (eGFR) slope and the urine albumin-to-creatinine ratio (UACR). These outcomes are monitored to understand patterns related to conditions marked by functional limitations. Data are still emerging for very advanced stages of kidney disease (e.g., stage G4/G5), and long-term effects are not fully established.


What is still uncertain about C-Flox

A number of research limitation frames apply to the current evidence. Data for certain groups, such as the frailest older adults or children, remain insufficient. Subgroup findings are uncertain, particularly regarding how outcomes may vary in patients with multiple, complex co-existing health conditions. The existing research provides context but not individual predictions, and research is ongoing to fill these identified gaps.

Frequently Asked Questions (FAQ)

Common questions about C-Flox (FAQ)


Q: What is the main reason C-Flox is prescribed?

C-Flox (Ciprofloxacin) is a prescription-only antibiotic that official regulatory documents state is used to treat a wide variety of specific bacterial infections. These approved uses include infections affecting the urinary tract, skin, bone, joint, and lower respiratory tract, as detailed in the official prescribing information.

Q: Is C-Flox considered a strong antibiotic?

Official information describes C-Flox as a potent, broad-spectrum fluoroquinolone. This classification means the drug is recognized as effective against a wide range of susceptible bacteria and has a bactericidal action, which means it is designed to directly kill the bacterial cells.

Q: Is C-Flox the same kind of medicine as penicillin?

No. Official classification shows that C-Flox is a fluoroquinolone antibiotic, which interferes with bacterial DNA essential for reproduction. Penicillins belong to a different drug class (beta-lactams) and have a distinct mechanism of action, often targeting the bacterial cell wall.

Q: Can C-Flox treat viral infections?

No. The official purpose of C-Flox is the elimination of susceptible bacterial infections. Regulatory documents state that it is not approved for and is not effective against infections caused by viruses, such as the common cold or influenza.

Q: Do you always have to finish the full course of C-Flox?

Official guidance states that the full course of treatment prescribed by the doctor is officially advised to be completed, even if symptoms begin to improve quickly. This practice is recommended to ensure the infection is fully eliminated and to minimize the risk of developing antibiotic resistance.

Q: Is it okay to drink caffeine while taking C-Flox?

C-Flox is known to reduce how quickly the body clears caffeine, potentially increasing its effects. Official documents advise caution, as this interaction may increase the risk of side effects like nervousness, restlessness, tremors, or difficulty sleeping.

Q: How long do side effects typically last after stopping C-Flox?

Most common side effects are generally expected to resolve once the drug is discontinued. However, official safety warnings note that certain serious adverse reactions, such as nerve damage (peripheral neuropathy) and tendon issues, may be disabling, long-lasting, or potentially irreversible.

Q: What happens if a person misses taking C-Flox at the usual time?

Regulatory guidance advises taking a missed dose as soon as you remember. However, if it is less than four hours until the next scheduled dose, official information states you should skip the missed dose and continue with the regular schedule, without taking a double dose.

Q: Are there published studies showing C-Flox's effectiveness for its main uses?

Yes. According to official documents, the drug's regulatory approval is grounded in extensive clinical trials and studies. These studies demonstrated its efficacy in treating its specified indications, such as complicated urinary tract and lower respiratory tract infections.

Q: What types of infections is C-Flox specifically approved to treat?

C-Flox is approved for the treatment of various bacterial infections. These specifically include infections of the urinary tract, lower respiratory tract, skin and skin structure, bones and joints, as well as complicated intra-abdominal infections and plague, based on official regulatory labels.

Q: Can C-Flox be used to treat urinary tract infections (UTIs)?

Yes. Official documents confirm that C-Flox is approved by regulatory agencies for the treatment of specific urinary tract infections (UTIs) when caused by susceptible types of bacteria.

Q: What should a patient do if they experience a severe allergic reaction to C-Flox?

C-Flox is contraindicated for anyone with a known allergy to it or any other fluoroquinolone drug. Official guidance states that if signs of a severe allergic reaction (such as hives, difficulty breathing, or swelling) occur, the medication should be immediately discontinued, and emergency medical services should be contacted for assistance.

Q: Can C-Flox interact with common pain relievers like ibuprofen?

Regulatory documents advise caution regarding co-administration with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. This is due to an officially documented, although rare, potential for increased Central Nervous System (CNS) stimulation, which could increase the risk of adverse effects like seizures.

Q: How is C-Flox eliminated from the body?

The official pharmacokinetics section of the prescribing information states that C-Flox is eliminated primarily through the kidneys. This occurs through both filtering the blood and actively moving the drug out of the bloodstream into the urine.

Q: Do official sources discuss C-Flox's impact on gut bacteria?

Yes. While not detailing the entire microbiome, the regulatory label explicitly warns of the risk of Clostridium difficile-associated diarrhea (CDAD). This condition results from an overgrowth of harmful bacteria in the gut following the disruption of the normal, protective gut flora by antibiotics.

Q: Is a metallic taste in the mouth a reported side effect of C-Flox?

Yes. Official documents and patient information confirm that an abnormal change in taste (dysgeusia), including a bad or metallic taste, has been reported as a documented side effect of C-Flox, particularly with the oral forms.

Q: What are the official recommendations regarding driving or operating machinery while on C-Flox?

Official warnings note that C-Flox can cause Central Nervous System (CNS) side effects such as dizziness, confusion, and visual changes. The drug label states that patients should determine how the drug affects their individual ability to drive or operate complex machinery before engaging in these activities.

Q: How is C-Flox generally classified by global health organizations?

C-Flox, which contains the active ingredient Ciprofloxacin, is officially classified by the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system. It is categorized as an antibacterial agent for systemic use under the fluoroquinolone class.

Q: Does C-Flox have a different name in other countries?

Yes. Official global listings show that the active ingredient, Ciprofloxacin, is sold under numerous brand names worldwide. Common international brand names include Ciproxin and Ciloxan, in addition to C-Flox.

Q: Do studies support using C-Flox for respiratory infections?

Yes. Official regulatory approvals confirm that C-Flox is supported by clinical studies and is approved for the treatment of specific lower respiratory tract infections, such as pneumonia, when they are caused by susceptible bacteria.

Q: What does the drug's patient leaflet say about alcohol consumption?

While specific contraindications related to alcohol are not listed in the patient leaflet, regulatory reviews advise caution. Alcohol consumption may potentially increase or worsen some of C-Flox’s side effects, such as dizziness, headache, or low blood sugar.

Q: Does C-Flox affect birth control pills?

Official studies indicate that C-Flox generally does not interfere with the effectiveness of most low-dose oral contraceptive pills. However, official guidance states that if severe side effects like vomiting or diarrhea occur, additional or alternative contraceptive precautions may be necessary.

How should C-Flox be stored and disposed of?

C-Flox (ciprofloxacin) must be stored under specific conditions to maintain stability, as required by regulatory labeling. All forms must be kept out of reach of children.

Storage Requirements

Dosage Form Required Condition
Tablets Store in a tightly closed container at 20, C to 25, C.
Reconstituted Suspension Store at 25, C and do not freeze. Stable for 14 days.
Injection Store between 5, C and 25, C and protect from light.

Disposal

Official disposal instructions advise against flushing C-Flox down the toilet or pouring it down a sink. Unused or expired medication should be disposed of using a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (such as dirt) in a sealed container before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of C-Flox found in:

A-Z Index: